Beigene (NASDAQ:ONC) Hits New 12-Month High – Still a Buy?

Beigene, Ltd. (NASDAQ:ONC) hit a new 52-week high during trading on Thursday . The stock traded as high as $268.45 and last traded at $259.00, with a volume of 710828 shares. The stock had previously closed at $259.70.

Beigene Stock Performance

The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $25.35 billion, a P/E ratio of -31.43, a P/E/G ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, research analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Insider Activity at Beigene

In related news, COO Xiaobin Wu sold 21,267 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. Insiders sold 58,123 shares of company stock worth $14,081,527 in the last ninety days. 7.43% of the stock is owned by company insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.